M&A Deal Summary

Blueprint Medicines Acquires Lengo Therapeutics

On November 29, 2021, Blueprint Medicines acquired life science company Lengo Therapeutics for 250M USD

Acquisition Highlights
  • This is Blueprint Medicines’ 1st transaction in the Life Science sector.
  • This is Blueprint Medicines’ largest (disclosed) transaction.
  • This is Blueprint Medicines’ 1st transaction in the United States.
  • This is Blueprint Medicines’ 1st transaction in California.

M&A Deal Summary
Date 2021-11-29
Target Lengo Therapeutics
Sector Life Science
Buyer(s) Blueprint Medicines
Deal Type Add-on Acquisition
Deal Value 250M USD
Advisor(s) Centerview Partners (Financial)
Cooley (Legal)

Target

Lengo Therapeutics

San Diego, California, United States
Lengo Therapeutics is a biopharmaceutical company committed to developing novel, small molecule precision therapeutics that target driver mutations in oncology. Lengo Therapeutics is based in San Diego, California.

Search 198,435 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Blueprint Medicines

Cambridge, Massachusetts, United States
Category Company
Founded 2008
Sector Life Science
Employees638
Revenue 249M USD (2023)
DESCRIPTION

Blueprint Medicines is a bio pharmaceutical company focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. Blueprint Medicines was founded in 2008 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal